Jordi Riba1, Sergio Romero, Eva Grasa, Esther Mena, Ignasi Carrió, Manel J Barbanoj. 1. Centre d'Investigació de Medicaments, Institut de Recerca, Servei de Farmacologia Clínica, Hospital de la Santa Creu i Sant Pau, and Departament de Farmacologia i Terapéutica, Universitat Autònoma de Barcelona, Spain. jriba@santpau.es
Abstract
RATIONALE: Ayahuasca is a South American psychoactive plant tea which contains the serotonergic psychedelic N,N-dimethyltryptamine (DMT) and monoamine-oxidase inhibitors that render DMT orally active. Previous investigations with ayahuasca have highlighted a psychotropic effect profile characterized by enhanced introspective attention, with individuals reporting altered somatic perceptions and intense emotional modifications, frequently accompanied by visual imagery. Despite recent advances in the study of ayahuasca pharmacology, the neural correlates of acute ayahuasca intoxication remain largely unknown. OBJECTIVES: To investigate the effects of ayahuasca administration on regional cerebral blood flow. METHODS:Fifteen male volunteers with prior experience in the use of psychedelics received asingle oral dose of encapsulated freeze-dried ayahuasca equivalent to 1.0 mg DMT/kg body weight and a placebo in a randomized double-blind clinical trial. Regional cerebral blood flow was measured 100-110 min after drug administration by means of single photon emission tomography (SPECT). RESULTS:Ayahuasca administration led to significant activation of frontal and paralimbic brain regions. Increased blood perfusion was observed bilaterally in the anterior insula, with greater intensity in the right hemisphere, and in the anterior cingulate/frontomedial cortex of the right hemisphere, areas previously implicated in somatic awareness, subjective feeling states, and emotional arousal. Additional increases were observed in the left amygdala/parahippocampal gyrus, a structure also involved in emotional arousal. CONCLUSIONS: The present results suggest that ayahuasca interacts with neural systems that are central to interoception and emotional processing and point to a modulatory role of serotonergic neurotransmission in these processes.
RCT Entities:
RATIONALE: Ayahuasca is a South American psychoactive plant tea which contains the serotonergic psychedelic N,N-dimethyltryptamine (DMT) and monoamine-oxidase inhibitors that render DMT orally active. Previous investigations with ayahuasca have highlighted a psychotropic effect profile characterized by enhanced introspective attention, with individuals reporting altered somatic perceptions and intense emotional modifications, frequently accompanied by visual imagery. Despite recent advances in the study of ayahuasca pharmacology, the neural correlates of acute ayahuasca intoxication remain largely unknown. OBJECTIVES: To investigate the effects of ayahuasca administration on regional cerebral blood flow. METHODS: Fifteen male volunteers with prior experience in the use of psychedelics received a single oral dose of encapsulated freeze-dried ayahuasca equivalent to 1.0 mg DMT/kg body weight and a placebo in a randomized double-blind clinical trial. Regional cerebral blood flow was measured 100-110 min after drug administration by means of single photon emission tomography (SPECT). RESULTS: Ayahuasca administration led to significant activation of frontal and paralimbic brain regions. Increased blood perfusion was observed bilaterally in the anterior insula, with greater intensity in the right hemisphere, and in the anterior cingulate/frontomedial cortex of the right hemisphere, areas previously implicated in somatic awareness, subjective feeling states, and emotional arousal. Additional increases were observed in the left amygdala/parahippocampal gyrus, a structure also involved in emotional arousal. CONCLUSIONS: The present results suggest that ayahuasca interacts with neural systems that are central to interoception and emotional processing and point to a modulatory role of serotonergic neurotransmission in these processes.
Authors: J Riba; A Rodríguez-Fornells; G Urbano; A Morte; R Antonijoan; M Montero; J C Callaway; M J Barbanoj Journal: Psychopharmacology (Berl) Date: 2001-02 Impact factor: 4.530
Authors: C S Grob; D J McKenna; J C Callaway; G S Brito; E S Neves; G Oberlaender; O L Saide; E Labigalini; C Tacla; C T Miranda; R J Strassman; K B Boone Journal: J Nerv Ment Dis Date: 1996-02 Impact factor: 2.254
Authors: J C Callaway; D J McKenna; C S Grob; G S Brito; L P Raymon; R E Poland; E N Andrade; E O Andrade; D C Mash Journal: J Ethnopharmacol Date: 1999-06 Impact factor: 4.360
Authors: L Hermle; M Fünfgeld; G Oepen; H Botsch; D Borchardt; E Gouzoulis; R A Fehrenbach; M Spitzer Journal: Biol Psychiatry Date: 1992-12-01 Impact factor: 13.382
Authors: Antonio Verdejo-García; María Del Mar Sánchez-Fernández; Luisa María Alonso-Maroto; Fermín Fernández-Calderón; Jose C Perales; Oscar Lozano; Miguel Pérez-García Journal: Psychopharmacology (Berl) Date: 2010-04-13 Impact factor: 4.530
Authors: José Carlos Bouso; Josep Maria Fábregas; Rosa Maria Antonijoan; Antoni Rodríguez-Fornells; Jordi Riba Journal: Psychopharmacology (Berl) Date: 2013-06-21 Impact factor: 4.530
Authors: Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak Journal: Ther Adv Psychopharmacol Date: 2016-03-18
Authors: Draulio B de Araujo; Sidarta Ribeiro; Guillermo A Cecchi; Fabiana M Carvalho; Tiago A Sanchez; Joel P Pinto; Bruno S de Martinis; Jose A Crippa; Jaime E C Hallak; Antonio C Santos Journal: Hum Brain Mapp Date: 2011-09-16 Impact factor: 5.038
Authors: Joaquim Soler; Matilde Elices; Alba Franquesa; Steven Barker; Pablo Friedlander; Amanda Feilding; Juan C Pascual; Jordi Riba Journal: Psychopharmacology (Berl) Date: 2015-11-27 Impact factor: 4.530